US7611713B2
(en)
|
1993-03-05 |
2009-11-03 |
Pharmexa Inc. |
Inducing cellular immune responses to hepatitis B virus using peptide compositions
|
US9340577B2
(en)
|
1992-08-07 |
2016-05-17 |
Epimmune Inc. |
HLA binding motifs and peptides and their uses
|
US7585622B1
(en)
|
1996-10-01 |
2009-09-08 |
Geron Corporation |
Increasing the proliferative capacity of cells using telomerase reverse transcriptase
|
US6183746B1
(en)
|
1997-10-09 |
2001-02-06 |
Zycos Inc. |
Immunogenic peptides from the HPV E7 protein
|
JP2002507397A
(ja)
*
|
1998-03-13 |
2002-03-12 |
エピミューン,インコーポレイティド |
Hla結合ペプチド及びその使用
|
EP1225907A4
(en)
*
|
1999-10-05 |
2005-06-22 |
Epimmune Inc |
INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODIC VIRUS-1 (HIV-1) BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS
|
JP2003516417A
(ja)
*
|
1999-12-06 |
2003-05-13 |
オピタル・サント−ジュスティーヌ |
糸球体濾過異常、動脈管開存、および骨粗鬆症治療に用いる組成物
|
US7462354B2
(en)
|
1999-12-28 |
2008-12-09 |
Pharmexa Inc. |
Method and system for optimizing minigenes and peptides encoded thereby
|
BR0017136A
(pt)
*
|
2000-02-23 |
2003-02-25 |
Epimmune Inc |
Peptìdeos de ligação ao hla e seus usos.
|
WO2002020616A1
(en)
*
|
2000-09-01 |
2002-03-14 |
Epimmune Inc. |
Hla-a2.1 binding peptides and their uses
|
US6974574B2
(en)
|
2001-08-16 |
2005-12-13 |
The General Hospital Corporation |
Methods of inducing an HIV specific response using a Vpr-specific epitope
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
PT1562972E
(pt)
|
2002-10-15 |
2010-11-10 |
Facet Biotech Corp |
Alteração de afinidades de ligação ao fcrn ou semi-vidas séricas de anticorpos por mutagénese
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
WO2005037867A1
(en)
|
2003-10-15 |
2005-04-28 |
Pdl Biopharma, Inc. |
ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
|
DE102005020911A1
(de)
*
|
2005-05-04 |
2006-11-16 |
Carl Zeiss Meditec Ag |
Verfahren zur Messung der Änderung des Polarisationszustands von polarisierter optischer Strahlung durch eine optisch aktive Schicht eines Körpers und/oder einer Konzentration eines optisch aktiven Stoffs in der Schicht und Vorrichtung zur Durchführung des Verfahrens
|
CA2614893A1
(en)
|
2005-07-06 |
2007-01-18 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine, In C. |
Stable quantitation and detection of immune response levels with non-zero background peptides
|
HUE025636T2
(en)
*
|
2007-07-27 |
2016-04-28 |
Immatics Biotechnologies Gmbh |
New immunogenic epitope for immunotherapy
|
EP2391635B1
(en)
|
2009-01-28 |
2017-04-26 |
Epimmune Inc. |
Pan-dr binding polypeptides and uses thereof
|
WO2012072088A1
(en)
|
2010-12-02 |
2012-06-07 |
Bionor Immuno As |
Peptide scaffold design
|
AU2012204955B2
(en)
|
2011-01-06 |
2016-10-06 |
Bionor Immuno As |
Monomeric and multimeric immunogenic peptides
|
NZ702146A
(en)
|
2012-06-06 |
2016-11-25 |
Bionor Immuno As |
Peptides derived from viral proteins for use as immunogens and dosage reactants
|
EP2745845A1
(en)
|
2012-12-19 |
2014-06-25 |
Centre Hospitalier Universitaire de Bordeaux |
A method for preventing or treating an HIV infection
|
CN105200010B
(zh)
*
|
2015-10-15 |
2019-02-12 |
首都医科大学附属北京佑安医院 |
艾滋病感染者hla-a2特异性ctl细胞的体外培养方法及其专用培养基
|